Laura Stoppel Ph.D. is a Partner on the Investment Team at RA Capital Management. She joined the CellCentric board in July 2024.

Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Acumen Pharmaceuticals, Indapta Therapeutics, Nimbus Therapeutics. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders.

Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.